NASDAQ:ZYXI Zynex (ZYXI) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free ZYXI Stock Alerts $11.46 -0.08 (-0.69%) (As of 10:55 AM ET) Add Compare Share Share Today's Range$11.39▼$11.8150-Day Range$10.94▼$13.7452-Week Range$6.88▼$13.77Volume29,783 shsAverage Volume230,052 shsMarket Capitalization$364.08 millionP/E Ratio49.83Dividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Zynex alerts: Email Address Zynex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside56.0% Upside$18.00 Price TargetShort InterestBearish33.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.19Based on 21 Articles This WeekInsider TradingN/AProj. Earnings Growth88.00%From $0.50 to $0.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector311th out of 909 stocksElectromedical Equipment Industry6th out of 21 stocks 3.5 Analyst's Opinion Consensus RatingZynex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZynex has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted33.01% of the float of Zynex has been sold short.Short Interest Ratio / Days to CoverZynex has a short interest ratio ("days to cover") of 26.7, which indicates bearish sentiment.Change versus previous monthShort interest in Zynex has recently decreased by 0.35%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldZynex does not currently pay a dividend.Dividend GrowthZynex does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYXI. Previous Next 2.3 News and Social Media Coverage News SentimentZynex has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Zynex this week, compared to 2 articles on an average week.Search Interest6 people have searched for ZYXI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Zynex to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynex insiders have not sold or bought any company stock.Percentage Held by Insiders52.13% of the stock of Zynex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.68% of the stock of Zynex is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Zynex are expected to grow by 88.00% in the coming year, from $0.50 to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynex is 50.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynex is 50.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 171.98.Price to Book Value per Share RatioZynex has a P/B Ratio of 11.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About Zynex Stock (NASDAQ:ZYXI)Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.Read More ZYXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYXI Stock News HeadlinesMay 3, 2024 | americanbankingnews.comZynex (NASDAQ:ZYXI) Rating Reiterated by HC WainwrightMay 3, 2024 | americanbankingnews.comZynex, Inc. to Post Q2 2024 Earnings of $0.08 Per Share, HC Wainwright Forecasts (NASDAQ:ZYXI)May 3, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...May 2, 2024 | finance.yahoo.comZynex, Inc. (NASDAQ:ZYXI) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comZynex Inc (ZYXI) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Seizing ...April 30, 2024 | msn.comZYXI Stock Earnings: Zynex Misses Revenue for Q1 2024April 30, 2024 | finance.yahoo.comZynex Inc (ZYXI) Q1 2024 Earnings: Revenue Meets Expectations, EPS Falls ShortApril 30, 2024 | prnewswire.comZynex Reports First Quarter 2024 Financial ResultsMay 3, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...April 29, 2024 | markets.businessinsider.comWhat Wall Street expects from Zynex's earningsApril 28, 2024 | finance.yahoo.comZynex, Inc. (ZYXI)April 26, 2024 | finance.yahoo.comInvesting in Zynex (NASDAQ:ZYXI) five years ago would have delivered you a 82% gainApril 18, 2024 | prnewswire.comZynex Sets First Quarter 2024 Earnings CallApril 2, 2024 | investorplace.com3 Industrial Stocks Short Sellers Are Hammering: Cracks in the Foundation?April 2, 2024 | prnewswire.comZynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition AwardMarch 30, 2024 | finance.yahoo.comWith 51% ownership, Zynex, Inc. (NASDAQ:ZYXI) insiders have a lot riding on the company's futureMarch 16, 2024 | finance.yahoo.comZYXI Aug 2024 20.000 callMarch 15, 2024 | wsj.comZynex Inc.March 3, 2024 | finance.yahoo.comZynex Full Year 2023 Earnings: Misses ExpectationsMarch 2, 2024 | seekingalpha.comZynex, Inc. (ZYXI) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comZynex, Inc. (NASDAQ:ZYXI) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | markets.businessinsider.comHere's what to expect from Zynex's earningsMarch 1, 2024 | finance.yahoo.comZynex Price Target Raised by RBC Capital, HC Wainwright AnalystsFebruary 29, 2024 | benzinga.comZynex: Q4 Earnings InsightsFebruary 29, 2024 | msn.comZynex GAAP EPS of $0.04 misses by $0.13, revenue of $47.28M misses by $8.34MFebruary 29, 2024 | finance.yahoo.comZynex Inc (ZYXI) Reports 17% Revenue Growth in FY 2023, Announces New $20 Million Stock ...February 29, 2024 | finance.yahoo.comZynex Reports Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive ZYXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:ZYXI CUSIPN/A CIK846475 Webwww.zynex.com Phone(303) 703-4906FaxN/AEmployees1,100Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$21.00 Low Stock Price Target$15.00 Potential Upside/Downside+56.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.23 Trailing P/E Ratio50.17 Forward P/E Ratio23.08 P/E GrowthN/ANet Income$9.73 million Net Margins4.33% Pretax Margin5.82% Return on Equity16.34% Return on Assets5.76% Debt Debt-to-Equity Ratio1.76 Current Ratio3.58 Quick Ratio4.03 Sales & Book Value Annual Sales$184.32 million Price / Sales1.99 Cash Flow$0.40 per share Price / Cash Flow28.60 Book Value$1.04 per share Price / Book11.10Miscellaneous Outstanding Shares31,770,000Free Float15,400,000Market Cap$366.63 million OptionableOptionable Beta0.49 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Thomas Sandgaard (Age 65)Founder, President, CEO & Chairman Comp: $992.83kMr. Daniel J. Moorhead (Age 52)Chief Financial Officer Comp: $472.61kMs. Anna Lucsok (Age 37)Chief Operating Officer Comp: $400.84kMr. Steve FoxVice President Of SalesMr. Donald GreggPresident of Zynex Monitoring SolutionsMr. Neil FrieryPresident & COO of Zynex Monitoring Solutions, Inc.More ExecutivesKey CompetitorsAxoGenNASDAQ:AXGNEdap TmsNASDAQ:EDAPSemler ScientificNASDAQ:SMLRElectromedNYSE:ELMDOutset MedicalNASDAQ:OMView All CompetitorsInsiders & InstitutionsHussman Strategic Advisors Inc.Sold 10,500 shares on 5/2/2024Ownership: 0.163%Janney Montgomery Scott LLCSold 33,553 shares on 5/1/2024Ownership: 0.282%BNP Paribas Financial MarketsSold 4,613 shares on 5/1/2024Ownership: 0.092%Allspring Global Investments Holdings LLCSold 7,990 shares on 4/30/2024Ownership: 0.027%Principal Financial Group Inc.Bought 6,378 shares on 4/29/2024Ownership: 0.055%View All Insider TransactionsView All Institutional Transactions ZYXI Stock Analysis - Frequently Asked Questions Should I buy or sell Zynex stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZYXI shares. View ZYXI analyst ratings or view top-rated stocks. What is Zynex's stock price target for 2024? 2 brokerages have issued 12-month price targets for Zynex's stock. Their ZYXI share price targets range from $15.00 to $21.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 56.0% from the stock's current price. View analysts price targets for ZYXI or view top-rated stocks among Wall Street analysts. How have ZYXI shares performed in 2024? Zynex's stock was trading at $10.89 at the beginning of 2024. Since then, ZYXI stock has increased by 6.0% and is now trading at $11.54. View the best growth stocks for 2024 here. How were Zynex's earnings last quarter? Zynex, Inc. (NASDAQ:ZYXI) posted its quarterly earnings results on Thursday, February, 29th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by $0.13. The company had revenue of $47.28 million for the quarter, compared to analyst estimates of $54.53 million. Zynex had a net margin of 4.33% and a trailing twelve-month return on equity of 16.34%. The business's revenue was down 3.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.20 earnings per share. What guidance has Zynex issued on next quarter's earnings? Zynex issued an update on its second quarter 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share (EPS) guidance of 0.080- for the period, compared to the consensus estimate of 0.070. The company issued revenue guidance of $52.0 million-, compared to the consensus revenue estimate of $53.1 million. What is Thomas Sandgaard's approval rating as Zynex's CEO? 81 employees have rated Zynex Chief Executive Officer Thomas Sandgaard on Glassdoor.com. Thomas Sandgaard has an approval rating of 87% among the company's employees. Who are Zynex's major shareholders? Zynex's stock is owned by a variety of institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (0.75%), Bridge City Capital LLC (0.58%), Congress Asset Management Co. MA (0.37%), Janney Montgomery Scott LLC (0.28%), Hussman Strategic Advisors Inc. (0.16%) and BNP Paribas Financial Markets (0.09%). Insiders that own company stock include Anna Lucsok, Daniel J Moorhead and Thomas Sandgaard. View institutional ownership trends. How do I buy shares of Zynex? Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZYXI) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithCould Your Accounts Be Frozen?Allegiance GoldDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
